Pharmaceutical - Mergers & Acquisitions, Pfizer

Filter

Popular Filters

1 to 25 of 32 results

UK M&A regulator consults on more stringent regulations

UK M&A regulator consults on more stringent regulations

16-09-2014

Partly in response to the recent (failed, thus far) attempt by US pharma giant Pfizer to acquire Anglo-Swedish…

LegalMergers & AcquisitionsPfizerPharmaceuticalUK

Pfizer could try to acquire Actavis as back-up to a further bid for AstraZeneca

Pfizer could try to acquire Actavis as back-up to a further bid for AstraZeneca

22-08-2014

While speculation continues as to whether Pfizer will resume its attempts to buy AstraZeneca, Pfizer…

ActavisAstraZenecaBusiness FinanceIrelandMergers & AcquisitionsPfizerPharmaceuticalSwedenUKUnited StatesUSA

Pfizer spends $635 million on acquiring two Baxter vaccines

Pfizer spends $635 million on acquiring two Baxter vaccines

30-07-2014

US pharma giant Pfizer has entered into a definitive agreement to acquire Baxter International portfolio…

Baxter InternationalMergers & AcquisitionsPfizerPharmaceuticalProductionUSAVaccines

UK Business Secretary to set out new takeover rules

UK Business Secretary to set out new takeover rules

13-07-2014

UK Business Secretary Vince Cable is shortly to announce new regulations to deal with foreign takeover…

LegalMergers & AcquisitionsPfizerPharmaceuticalUKVince Cable

Pfizer inks multi-million $ cancer immunology deal with Cellectis

Pfizer inks multi-million $ cancer immunology deal with Cellectis

18-06-2014

France-based genome engineering specialist Cellectis saw its shares rocket nearly 50% to 9.26 euros,…

CellectisLicensingMergers & AcquisitionsOncologyPfizerPharmaceutical

In Focus: Strong drivers will keep the pharma M&A pipeline bubbling

In Focus: Strong drivers will keep the pharma M&A pipeline bubbling

28-05-2014

The record start to 2014’s pharma M&A has been a welcome boost to a deal market that had been in the…

CancerGlobalInterviewsMergers & AcquisitionsPfizerPharmaceuticalPharmaceutical industryPharmaceutical sciences

AstraZeneca safe (for now?) as Pfizer walks away from pursuit of the firm

26-05-2014

US pharma giant Pfizer, which has been involved in a controversial pursuit of UK-based AstraZeneca, has…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

AstraZeneca rejects Pfizer’s improved and “final” offer of £55 a share

AstraZeneca rejects Pfizer’s improved and “final” offer of £55 a share

19-05-2014

After what must have been a hectic weekend of cross Atlantic activity, the board of Anglo-Swedish drug…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

AstraZeneca accuses Pfizer of opportunism, as UK investigation kicks off

AstraZeneca accuses Pfizer of opportunism, as UK investigation kicks off

13-05-2014

As the arguments continue over the benefits or otherwise of US pharma giant Pfizer’s £63 billion ($106…

AstraZenecaMergers & AcquisitionsPfizerPharmaceuticalPoliticsUK

AstraZeneca sets out its value stall, projecting annual revenues of $45 billion by 2023

AstraZeneca sets out its value stall, projecting annual revenues of $45 billion by 2023

06-05-2014

In a bid to explain its rejection of US pharma giant Pfizer’s increased takeover bid for the Anglo-Swedish…

AstraZenecaFinancialMergers & AcquisitionsPfizerPharmaceuticalResearch

Pfizer’s 4th-qtr 2014 profits and sales slump on generic competition

Pfizer’s 4th-qtr 2014 profits and sales slump on generic competition

06-05-2014

US pharma giant Pfizer, which is aggressively pursuing a takeover of Anglo-Swedish drug major AstraZeneca,…

AstraZenecaFinancialMergers & AcquisitionsPfizerPharmaceutical

AstraZeneca board rejects Pfizer’s increased offer

AstraZeneca board rejects Pfizer’s increased offer

02-05-2014

Within just a few hours of US pharma giant Pfizer announcing an increased offer price for Anglo-Swedish…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

Pfizer sweetens takeover offer for AstraZeneca to £50 a share

Pfizer sweetens takeover offer for AstraZeneca to £50 a share

02-05-2014

After much speculation and a lightning visit by Pfizer’s chief executive Ian Read to the UK to woo…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

AstraZeneca says Pfizer offer “very significantly” undervalues the firm

28-04-2014

Confirming a takeover approach from the US drugs giant, Anglo-Swedish pharma major AstraZeneca issued…

AstraZenecaMergers & AcquisitionsOncologyPfizerPharmaceutical

Pfizer goes public, confirming pursuit of AstraZeneca

Pfizer goes public, confirming pursuit of AstraZeneca

28-04-2014

US pharma giant Pfizer this morning confirmed that it previously submitted a preliminary, non-binding…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

Pfizer said to be eyeing a $100 billion bid for AstraZeneca

20-04-2014

USA-based Pfizer, the world’s largest pharma company by sales, looks to be on the acquisition trail,…

AstraZenecaMergers & AcquisitionsPfizerPharmaceutical

Pfizer to separate business into three units: will this lead to spin-outs?

29-07-2013

Moving in a direction already advocated by several analysts, US pharma behemoth Pfizer (NYSE: PFE) today…

GenericsManagementMergers & AcquisitionsPfizerPharmaceutical

Pfizer to split-off remaining 80% interest in Zoetis

22-05-2013

Zoetis Inc (Nasdaq: ZTS), the animal health business of which US pharma behemoth Pfizer (NYSE: PFE) spun…

FinancialMergers & AcquisitionsPfizerPharmaceuticalZoetis

Zoetis IPO caps strong month for life sciences financings, says Burrill & Co

04-02-2013

Life sciences financing activity got a strong start in the New Year as companies raised $10.3 billion…

AllerganBiotechnologyFinancialMAP PharmaceuticalsMergers & AcquisitionsPfizerPharmaceuticalZoetis

Pfizer's Zoetis spin-off could raise $12 billion; BGI-Shenzhen updates on Complete Genomics deal

20-01-2013

Pfizer (NYSE: PFE), the world's largest drugmaker by sales, which has previously said it is spinning…

BGI-ShenzhenBiotechnologyComplete GenomicsFinancialMergers & AcquisitionsPfizerPharmaceuticalZoetis

GlobalData views potential of Pfizer's rumored acquisition of Strides' Agila unit

20-01-2013

As drug makers continue to jostle for market share and deal with declining revenues from their off-patent…

Agila SpecialitesGenericsMergers & AcquisitionsPfizerPharmaceuticalStrides Arcolab

Teva to raise stake in Rexahn; Pfizer completes NextWave deal

28-11-2012

US clinical-stage biopharma company focused on oncology and central nervous system (CNS) therapeutics…

Mergers & AcquisitionsNeurologicalNextWave PharmaceuticalsNorth AmericaOncologyPfizerPharmaceuticalQuillivantResearchRexahn PharmaceuticalsRX-3117Teva Pharmaceutical Industries

1 to 25 of 32 results

Back to top